Case Studies: Determining Appropriate Transitions from Intravenous to Subcutaneous Anti-PD-1 Formulations

Best answer: (A) Yes. He has completed induction ipilimumab/nivolumab and is transitioning to nivolumab monotherapy maintenance.

Rationale: The FDA approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) in December 2024 for subcutaneous injection across approved adult solid tumor nivolumab indications, including as monotherapy maintenance following completion of IV nivolumab plus ipilimumab combination therapy in unresectable or metastatic melanoma. Importantly, Opdivo Qvantig is not approved for concurrent use with IV ipilimumab. It may only be substituted for IV nivolumab during the monotherapy phase.¹

This patient has completed his 4-cycle induction and is now entering the maintenance monotherapy phase, making him an appropriate candidate for the switch. His prior grade 2 transaminitis, which has resolved, does not preclude the transition; the immune-related adverse event profile of SC nivolumab is comparable to IV nivolumab.

The NCCN Cutaneous Melanoma Guidelines state that nivolumab and hyaluronidase-nvhy SC injection may be substituted for IV nivolumab, noting that it has different dosing and administration instructions compared to IV nivolumab.²

The medical oncologist discusses the option of SC nivolumab with the patient. Before making a final decision, the patient wants to understand the practical differences between the two formulations.

Best answer: (C) SC nivolumab reduces administration time from 30–60 minutes to less than 5 minutes and eliminates the need for IV access.

Rationale: In the phase I/II CheckMate 8KX study, the mean duration of SC nivolumab injection was less than 5 minutes, compared with the 30-minute IV infusion plus additional time for IV line placement, flushing, and post-infusion monitoring.³

The phase III CheckMate 67T trial demonstrated pharmacokinetic noninferiority and comparable objective response rates between SC and IV nivolumab, with no new safety signals.⁴

A systematic review and meta-analysis of SC versus IV PD-1/PD-L1 inhibitors across 1,243 patients confirmed no significant differences in overall survival, progression-free survival, objective response rate, or adverse events between the two routes.⁵

SC administration does not eliminate clinic visits entirely. Patients still require periodic monitoring, laboratory assessments, and clinical evaluations, but it substantially reduces chair time and eliminates the need for venipuncture for drug delivery. For this patient with difficult IV access and significant time constraints, these are clinically meaningful benefits. Patient preference studies consistently show that the majority of patients prefer SC over IV delivery, citing convenience, reduced venipunctures, and shorter visits as major advantages.

The oncologist decides to transition the patient to SC nivolumab and hyaluronidase-nvhy 1,200 mg/20,000 units every 4 weeks. At his first SC administration visit, the nurse administers the injection in approximately 3–5 minutes. He is monitored briefly and discharged. He reports high satisfaction at his follow-up visit, noting that the entire clinic visit took under 45 minutes compared to his previous 4–5 hour visits for IV infusion.

Best answer: (C) SC nivolumab offers comparable pharmacokinetics, efficacy, and safety to IV nivolumab while reducing administration time, eliminating IV access requirements, and improving patient convenience.

Rationale: In the phase I/II CheckMate 8KX study, the mean duration of SC nivolumab injection was less than 5 minutes, compared with the 30-minute IV infusion plus additional time for IV line placement, flushing, and post-infusion monitoring.³

The phase III CheckMate 67T trial demonstrated pharmacokinetic noninferiority and comparable objective response rates between SC and IV nivolumab, with no new safety signals.⁴

A systematic review and meta-analysis of SC versus IV PD-1/PD-L1 inhibitors across 1,243 patients confirmed no significant differences in overall survival, progression-free survival, objective response rate, or adverse events between the two routes.⁵

SC administration does not eliminate clinic visits entirely. Patients still require periodic monitoring, laboratory assessments, and clinical evaluations, but it substantially reduces chair time and eliminates the need for venipuncture for drug delivery. For this patient with difficult IV access and significant time constraints, these are clinically meaningful benefits. Patient preference studies consistently show that the majority of patients prefer SC over IV delivery, citing convenience, reduced venipunctures, and shorter visits as major advantages.

The oncologist decides to transition the patient to SC nivolumab and hyaluronidase-nvhy 1,200 mg/20,000 units every 4 weeks. At his first SC administration visit, the nurse administers the injection in approximately 3–5 minutes. He is monitored briefly and discharged. He reports high satisfaction at his follow-up visit, noting that the entire clinic visit took under 45 minutes compared to his previous 4–5 hour visits for IV infusion.

Best answer: (C) Pembrolizumab and nivolumab have comparable safety and irAE profiles regardless of IV or SC administration; for patients with BRAF V600E mutations, targeted therapy with dabrafenib/trametinib represents an equally effective adjuvant alternative that completely avoids immune-mediated toxicities.

Rationale: Pembrolizumab and nivolumab are both anti-PD-1 monoclonal antibodies with comparable mechanisms of action and similar immune-related adverse event (irAE) profiles. Neither agent has demonstrated a clearly superior safety profile over the other in the adjuvant setting. The subcutaneous formulations preserve the same irAE rates as their IV counterparts; the route of administration does not meaningfully alter the risk of immune-mediated toxicity (though mild injection site reactions are slightly more common with SC delivery).^1,2

For this patient with a strong family history of autoimmune disease and BRAF V600E-mutant melanoma, the most important counseling point is that adjuvant dabrafenib/trametinib is also an effective alternative that avoids the approximately 15% risk of lifelong endocrine dysfunction and other irAEs associated with anti-PD-1 therapy.⁶

NCCN guidelines note that there is no good evidence basis for selecting between adjuvant BRAF/MEK inhibitors versus immune checkpoint inhibitors, as both have similar efficacy.⁵

Side effects from immune checkpoint inhibitor therapy tend to be longer lasting than those from BRAF/MEK inhibitor therapy, persisting after discontinuation of treatment.⁸

If the patient still prefers immunotherapy, either subcutaneous pembrolizumab or nivolumab would be appropriate. Given her proximity to the cancer center, the dosing interval (Q3W vs Q4W vs Q6W) is less of a differentiating factor.

Best answer: (C) SC nivolumab offers comparable pharmacokinetics, efficacy, and safety to IV nivolumab while reducing administration time, eliminating IV access requirements, and improving patient convenience.

Rationale: The rationale for favoring SC nivolumab in appropriate candidates rests on several converging lines of evidence:

• Pharmacokinetic noninferiority: The phase III CheckMate 67T trial demonstrated that SC nivolumab met predefined noninferiority thresholds for both time-averaged serum concentration and trough concentration at steady state compared to IV nivolumab⁴
• Similar safety profile: No new safety signals were observed. The incidence and severity of immune-related adverse events were comparable. Local injection site reactions with SC were mild (grade 1–2) and mostly self-resolving.⁴
• Dramatically reduced administration time: SC injection takes less than 5 minutes versus 30+ minutes for IV infusion, with additional time savings from eliminating IV line placement, flushing, and extended post-infusion monitoring.⁴
• Elimination of IV access challenges: For patients with poor venous access, a common problem in cancer patients who have undergone multiple cycles of therapy, SC administration removes a significant source of discomfort and procedural delay.
• Patient preference: In CheckMate 8KX, patients preferred SC delivery over IV or had no preference.3 A crossover study of SC versus IV pembrolizumab found that 65% of patients preferred SC, with the most common reason being less time in clinic.⁶
• Health system benefits: SC administration reduces infusion chair occupancy, nursing time, and pharmacy preparation burden, optimizing infusion center capacity.²

While SC nivolumab achieves higher absolute drug exposure than IV nivolumab (geometric mean ratio of ~2.0 for time-averaged concentration), this is within the established safe therapeutic window and does not translate to clinically meaningful differences in efficacy or toxicity.⁶ SC nivolumab should not replace IV nivolumab during the combination phase with ipilimumab, as it is not approved for concurrent use with ipilimumab.

Best answer: (A) Switching directly from IV to subcutaneous nivolumab is supported by product labeling as an intra-drug route change, whereas switching to subcutaneous pembrolizumab represents a change in the therapeutic agent that warrants a separate clinical discussion.

Rationale: The FDA label for Opdivo Qvantig explicitly states that adult patients currently receiving IV nivolumab as a single agent may switch to subcutaneous Opdivo Qvantig at their next scheduled dose.¹ This is a straightforward route-of-administration switch within the same drug. Similarly, the Keytruda Qlex label supports switching between IV and SC pembrolizumab.²

However, switching from nivolumab to pembrolizumab (or vice versa) represents a change in the therapeutic agent itself, not merely the route of administration. While nivolumab and pembrolizumab are both anti-PD-1 antibodies with similar mechanisms and are considered interchangeable by some experts, the pivotal adjuvant trials studied each agent independently, and the FDA approvals are drug-specific. A switch between agents mid-treatment should involve a clinical discussion about the rationale, and the decision should be documented.

In this case, the most straightforward approach is to switch from IV nivolumab to SC nivolumab (Opdivo Qvantig) 1,200 mg Q4W, maintaining the same drug and dosing interval while eliminating the need for IV infusion. If the patient strongly prefers the Q6W schedule, a discussion about switching to SC pembrolizumab Q6W is reasonable, acknowledging that this is a drug change rather than a simple formulation switch.

Best answer: (D) Neither pembrolizumab nor nivolumab requires renal dose adjustment, but subcutaneous pembrolizumab requires a substantially smaller injection volume (4.8 mL Q6W vs. 20 mL Q4W for nivolumab), which may guide patient comfort and preference.

Rationale: Anti-PD-1 antibodies are large monoclonal antibodies that are not renally cleared, and neither pembrolizumab nor nivolumab requires dose adjustment for renal impairment. This patient’s CKD stage 3b (eGFR 48) does not affect the choice between agents or necessitate dose modification.
Regarding injection volume, there is a notable difference between the two SC formulations:

• Keytruda Qlex Q6W: 4.8 mL injected over ~2 minutes (or 2.4 mL Q3W over ~1 minute)¹
• Opdivo Qvantig Q4W: 20 mL injected over 3–5 minutes (1,200 mg/20,000 units)²

The substantially smaller injection volume of SC pembrolizumab may be relevant for patients concerned about injection site discomfort or those with limited subcutaneous tissue. In clinical studies, injection site reactions with both formulations were predominantly grade 1–2 and self-limiting. However, the smaller volume of pembrolizumab SC (4.8 mL vs 20 mL) is a practical differentiator that may influence patient preference and comfort.